In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...
Hosted on MSN
Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships
CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results